SCHEMBL23089809

SCHEMBL23089809

COC(=O)[C@H]1CC[C@@H]1NC(=O)OCc1ccccc1

nearest known ligand 0.90

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CPB1 P15086 2/20 0.90
CYP2C9 P11712 2/20 0.58
CYP2C19 P33261 2/20 0.58
TSHR P16473 2/20 0.58
ALDH1A1 P00352 2/20 0.58
CYP1A2 P05177 1/20 0.58
POLB P06746 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2D6 P10635 1/20 0.58
GAA P10253 1/20 0.54
LMNA P02545 1/20 0.54
CTSB P07858 2/20 0.50
CTSS P25774 2/20 0.50
CTSK P43235 2/20 0.50
CTSL P07711 1/20 0.50
CASP3 P42574 3/20 0.49
EPHX1 P07099 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12193443 1.00 CPB1 (0.90) CPB1CYP2C9CYP2C19TSHRALDH1A1
SCHEMBL2497897 1.00 CPB1 (0.90) CPB1CYP2C9CYP2C19TSHRALDH1A1
SCHEMBL30059391 1.00 CPB1 (0.90) CPB1CYP2C9CYP2C19TSHRALDH1A1
SCHEMBL28376595 0.92 CPB1 (0.78) CPB1CYP2C9CYP2C19TSHRALDH1A1
SCHEMBL13712268 0.92 CPB1 (0.78) CPB1CYP2C9CYP2C19TSHRALDH1A1
SCHEMBL14161287 0.92 CPB1 (0.78) CPB1CYP2C9CYP2C19TSHRALDH1A1
SCHEMBL4481541 0.92 CPB1 (0.78) CPB1CYP2C9CYP2C19TSHRALDH1A1
SCHEMBL10303639 0.92 CPB1 (0.78) CPB1CYP2C9CYP2C19TSHRALDH1A1
SCHEMBL30135204 0.92 CPB1 (0.77) CPB1TSHRALDH1A1GAACTSB
SCHEMBL10916791 0.91 CPB1 (0.77) CPB1CYP2C9CYP2C19TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600711-B2 Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors KEZAR LIFE SCIENCES, INC. (US) 2026-04-14 US disclosed
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2023-02-14 US disclosed
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-12-22 US disclosed
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2021-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors SEC61B, SEC61A1, SEC61G CPB1 261/4885CYP2C9 1194/4885CYP2C19 1060/4885
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G CPB1 295/4885CYP2C9 978/4885CYP2C19 780/4885
US-12600711-B2 Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors CD274, CD40, ICOS CPB1 3223/4885CYP2C9 4302/4885CYP2C19 4176/4885
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G CPB1 159/4885CYP2C9 902/4885CYP2C19 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.